PRESS CONFERENCE SCHEDULE
Conference on Retroviruses and Opportunistic Infections/CROI 2017

All press conferences will be held in room 400 of the Washington State Convention Center. Embargoes on research presented in CROI press conferences lift at the lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are PST.

CROI press conferences are simulcast on http://www.croiconference.org/.

Monday, February 13, 3:00 – 3:45 pm

3:00 – 3:20 pm CHAIRED BY Susan Buchbinder, CROI Chair and University of California San Francisco, CA, US

WELCOME AND OVERVIEW OF CROI 2017
Susan P. Buchbinder, CROI Chair and University of California San Francisco, CA, US
Judith Currier, CROI Vice Chair and University of California Los Angeles, CA, US
– and –
Richard Koup, CROI Vice Chair and National Institute of Allergy and Infectious Diseases, US

3:20 – 3:45 PM CHAIRED BY Joseph Eron, University of North Carolina Chapel Hill, Chapel Hill, NC, US

ORAL ABSTRACT SESSION 4 -- NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE
(PRESENTED TUESDAY, FEBRUARY 14, 10:00 AM - 12:00 PM)

38. Discovery of Novel Potent HIV Capsid Inhibitors With Long-Acting Potential
Winston Tse, Gilead Scis, Inc, Foster City, CA, US

41. Randomized Trial of Bictegravir or Dolutegravir with FTC/TAF for Initial HIV Therapy
Paul Sax, Brigham and Women’s Hosp, Boston, MA, US

43. Prevalence and Impact of Pretreatment Drug Resistance in the ANRS 12249 TasP Trial
Anne Derache, Africa Hlth Rsr Inst, Mtubatuba, South Africa

44LB. Phase III SWORD 1&2: Switch to DTG+RPV Maintains Virologic Suppression Through 48 Wks
Josep M. Llibre, Univ Hosp Germans Trias, Badalona, Barcelona, Spain
Conference on Retroviruses and Opportunistic Infections/CROI 2017

All press conferences will be held in room 400 of the Washington State Convention Center. Embargoes on research presented in CROI press conferences lift at the lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are PST.

CROI press conferences are simulcast on http://www.croiconference.org/.

Tuesday, February 14, 12:15 – 1:15 pm

12:15 – 12:40 PM  Chaired by Elaine Abrams, Columbia University, New York, NY, US

**ORAL ABSTRACT SESSION 2 – CRITICAL ISSUES IN WOMEN’S HEALTH, MTCT, AND HIV TREATMENT IN CHILDREN**
(PRESENTED TUESDAY, FEBRUARY 14, 10:00 AM - 12:00 PM)

22. Randomized Trial of LEEP vs Cryotherapy to Treat CIN2/3 in HIV-Infected Women
Sharon Greene, Univ of Washington, Seattle, WA, US

24. Integration of Postnatal Services Improves MCH and ART Outcomes: a Randomised Trial
Landon Myer, Univ of Cape Town, Cape Town, South Africa

25. Adverse Birth Outcomes Differ by ART Regimen from Conception in Botswana
Rebecca Zash, Beth Israel Deaconess Med Ctr, Boston, MA, US

26. Effect of Point-of-Care Testing on Antiretroviral-Therapy Initiation Rates in Infants
Ilesh Jani, Instituto Nacional de Saude, Maputo, Mozambique

27. Treatment of Acute HIV Infection in Neonates
Louise Kuhn, Columbia Univ, New York, NY, US

12:40 – 12:55 PM  Chaired by Harold W. Jaffe, US Centers for Disease Control and Prevention, Atlanta, GA, US

**ORAL ABSTRACT SESSION 3 – HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND UNDERTREATED HIV EPIDEMIC**
(PRESENTED TUESDAY, FEBRUARY 14, 10:00 AM - 12:00 PM)

30. HIV Incidence, Prevalence, and Undiagnosed Infections in Men Who Have Sex With Men
Sonia Singh, CDC, Atlanta, GA, US

Nicole Crepaz CDC, Atlanta, GA, US

34LB. Combination HIV Prevention and HIV Incidence in Rakai, Uganda
Mary Grabowski, The Johns Hopkins Univ, Baltimore, MD, US

12:55 – 1:15 PM  Chaired by David Thomas, Johns Hopkins School of Medicine, Baltimore, MD, US

**POSTER SESSION – EMERGING VIRUSES: ZIKA VIRUS**
(PRESENTED TUESDAY, FEBRUARY 14, 2:30 - 4:00 PM)

**THEMED DISCUSSION 17 – EMERGING VIRUSES: THE ZIKA VIRUS**
(PRESENTED THURSDAY, FEBRUARY 16, 1:30 - 2:30 PM)

1055LB. Zika Virus Persistence in Body Fluids
Gabriela Paz-Bailey, CDC, Atlanta, GA, USA
1056 LB. Neurologic Consequences of Postnatal Zika Virus Infection in Infants
Maud Mavigner, Emory Univ, Atlanta, GA, USA

1057LB. Zika Virus Protection by a Single Low-dose Nucleoside-modified mRNA Vaccination
Michael Hogan, Univ of Pennsylvania, Philadelphia, PA, USA
Conference on Retroviruses and Opportunistic Infections/CROI 2017

All press conferences will be held in room 400 of the Washington State Convention Center. Embargoes on research presented in CROI press conferences lift at the lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are PST. CROI press conferences are simulcast on http://www.croiconference.org/.

Wednesday, February 15, 12:15 – 1:15 pm

12:15 – 12:35 PM  Chaired by Constance Benson, University of California at San Diego, CA, US

**ORAL ABSTRACT SESSION 7 – TB AND OTHER OPPORTUNISTIC INFECTIONS**
(PRESENTED WEDNESDAY, FEBRUARY 15, 10:00 AM - 12:00 PM)

76LB. A Multicenter Diagnostic Accuracy Study of the Xpert Ultra for Tuberculosis Diagnosis
Timothy Rodwell, FIND, Geneva, Switzerland

78. Six-month IPT Reduces Mortality Independently of ART in African Adults with High CD4
Anani Badje, INSERM, Bordeaux, France

81LB. Randomized Controlled Trial of Prednisone for Prevention of Paradoxical TB-IRIS
Graeme Meintjes, Univ of Cape Town, Cape Town, South Africa

12:35 – 12:55 PM  Chaired by Wafaa El-Sadr, ICAP at Columbia University, New York, NY, US

**ORAL ABSTRACT SESSION 8 – COMMON BEDFELLOWS: PREP, STIS, AND THE MICROBIOME**
(PRESENTED WEDNESDAY, FEBRUARY 15, 10:00 AM - 12:00 PM)

84. Resistance Emergence in Macaques Administered Cabotegravir LA During Acute Infection
Gerardo Garcia-Lerma, CDC, Atlanta, GA, US

85. Daily Oral PrEP is Effective Among Women with Abnormal Vaginal Microbiota
Renee Heffron, Univ of Washington, Seattle, WA, US

86LB. Impact of Vaginal Microbiota on Genital Tissue and Plasma Concentrations of Tenofovir
Sharon Hillier, Univ of Pittsburgh, Pittsburgh, PA, US

91LB. On Demand Post Exposure Prophylaxis with Doxycycline for MSM Enrolled in a PrEP Trial
Jean-Michel Molina, St. Louis, Hosp, Paris, France

12:55 – 1:15 PM  Chaired by Susan Buchbinder, CROI Chair and University of California San Francisco, CA, US

**POSTER SESSION 4 – HIV AND SUBSTANCE USE: DOUBLE TROUBLE**
(PRESENTED WEDNESDAY, FEBRUARY 15, 2:30 PM - 4:00 PM)

**THEMED DISCUSSION SESSION 14 – HIV AND SUBSTANCE USE: DOUBLE TROUBLE**
(PRESENTED THURSDAY, FEBRUARY 16, 1:30 PM - 2:30 PM)

869. "Hooked on Painkillers" Prior to First Injection among PWID in 16 U.S. Cities
Dita Broz, CDC, Atlanta, GA, US
871. Changes in Prescription Opioid, Meth, and Cocaine Use Among MSM in 20 U.S. Cities
Brooke Hoots, CDC, Atlanta, GA, US

873. Increasing Methamphetamine Use Among Non-MSM who Inject Drugs in King County, WA
Sara Glick, Univ of Washington, Seattle, WA, US

Please note the following special Meet-the-Expert media availability session, to be held in the CROI media room

3:00 PM

ORAL ABSTRACT SESSION 5 – ROLE OF HOST AND IMMUNE FACTORS IN HIV INFECTION
(PRESENTED WEDNESDAY, FEBRUARY 15, 10:00 AM - 12:00 PM)

64LB. Virion Incorporation of Integrin α4β7: Implications for HIV-1 Pathogenesis
Christina Guzzo, NIAID, Bethesda, MD, US

Anthony Fauci, NIAID, Bethesda, MD, US (via audio link)
Conference on Retroviruses and Opportunistic Infections/CROI 2017

All press conferences will be held in room 400 of the Washington State Convention Center. Embargoes on research presented in CROI press conferences lift at the lift at the end of the press conference panel or at the end of the conference session in which the study is presented, whichever is earlier. All times listed are PST.

CROI press conferences are simulcast on http://www.croiconference.org/.

Thursday, February 16, 12:15 – 1:15 pm

12:15 – 12:35 PM  Chaired by David Thomas, Johns Hopkins School of Medicine, Baltimore, MD, US

**Oral Abstract Session 9 – Hepatitis C: Problems and Progress** (Presented Thursday, February 16, 10:00 AM - 12:00 PM)

135. Modeling HIV-HCV Epidemiology in the DAA Era: the Road to Eradication
Victor Virlogeux, INSERM, Lyon, France

137LB. Substantial Decline in Acute HCV Infections Among Dutch HIV+ MSM After DAA Roll Out
Bart Rijnders, Erasmus Univ Med Ctr, Rotterdam, Netherlands

12:35 – 12:55 PM  Chaired by Peter Hunt, University of California San Francisco, CA, US

**Oral Abstract Session 12 – Inflammation and Age-Related Complications** (Presented Thursday, February 16, 10:00 AM - 12:00 PM)

126. IL-1β Inhibition Significantly Reduces Atherosclerotic Inflammation in Treated HIV
Priscilla Hsue, Univ of California San Francisco, San Francisco, CA, US

128LB. Association Between Cardiovascular Disease & Contemporarily Used Protease Inhibitors
Lene Ryom, CHIP, Copenhagen, Denmark

131. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in the D:A:D Study
Leah Shepherd, Univ Coll London, London, UK

12:55 – 1:15 PM  Chaired by Peter Hunt, University of California San Francisco, CA, US

**Oral Abstract Session 11 – HIV Persistence and Reactivation** (Presented Thursday, February 16, 10:00 AM - 12:00 PM)

119LB. Viral Control Induced by HIVconsv Vaccines & Romidepsin in Early Treated Individuals
Beatriz Mothe, IrsiCaixa AIDS Rsr Inst, Badalona, Spain

120. No Evidence of Ongoing HIV Replication After 7 Years on ART
Mary Kearney, NCI, Frederick, MD, US

**Poster Session 4 – HIV Persistence: Send in the Clones** (Presented Thursday, February 16, 2:30 - 4:30 PM)

299LB. Resurgence of HIV-1 Founder Viruses Following Antiretroviral Treatment Interruption
Morgane Rolland, US Military HIV Rsr Prog, Silver Spring, MD, US